Uncategorized

[Washington University in St. Louis] Nicholas O. Davidson, MD, DSc, the John E. and Adaline Simon Professor of Medicine and chief of the Division of Gastroenterology at WashU Medicine, has been named the recipient of the 2026 Distinguished Mentor Award from the American Gastroenterological Association.

[Cell Stem Cell] Researchers showed that loss of GATA6 drives lineage plasticity and fuels colorectal cancer liver metastasis by activating fetal-like and basal-like transcriptional programs.

[Nature Communications] Scientists showed, through metagenomic and metabolomic analyses of clinical cohorts, that Fusobacterium periodonticum is significantly enriched in colorectal cancer patients and strongly correlated with elevated decanoic acid levels.

[Cell Death & Disease] The authors investigated the regulatory pathway controlling MUC2 expression and O-glycosylation in colorectal cancer and assessed the therapeutic potential of rosiglitazone in restoring mucosal integrity.

[Cell Death & Disease] Researchers identified EF-hand domain family member D2 (EFHD2) as a key driver of colorectal cancer radioresistance, promoting lactate-dependent DNA repair and immune evasion through the HMGB1/HIF-1α signaling axis.

[Stem Cell Research & Therapy] Scientists engineered tumor-targeting 3D exosomes to deliver miR-99b-5p, inducing ferroptosis and enhancing chemotherapy response in colorectal cancer by inhibiting the FGFR3/PI3K/AKT pathway.

[American Journal of Physiology-Gastrointestinal and Liver Physiology] The authors showed that epithelial fucosylation regulates intestinal stem cell differentiation through Notch signaling, highlighting a role for 2′-fucosyllactose in supporting intestinal development and gut health.

[Cell Death Discovery] Scientists highlight how Helicobacter pylori (H. pylori)-induced epigenetic reprogramming locks gastric cancer cells into a drug-resistant hybrid epithelial–mesenchymal state.

[Nature Biomedical Engineering] Scientists developed a programmable RNA engineering platform, termed the 3′UTR CRISPR/dCas13 Engineering System, to precisely manipulate mRNA alternative polyadenylation in vivo.

[UCLA Health] Researchers from the UCLA Health Jonsson Comprehensive Cancer Center have received a $1.7 million grant from the US Department of Defense’s Congressionally Directed Medical Research Programs to develop new strategies to improve CAR T-cell therapies for metastatic CRPC.

[Communications Biology] Scientists provide distinct insight into how FOXA1 forkhead DNA-binding domain (FKHD) mutations drive prostate cancer progression and highlight potential therapeutic targets in tumors.

[Molecular Aspects of Medicine] The authors summarize the key molecular drivers of prostate cancer resistance and evaluates emerging invasive biomarkers with potential clinical utility.